Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy.
BACKGROUND
The efficacy of positron emission tomography with 18F fluoro-2-deoxy-D-glucose (FDG-PET) is obscure in evaluating viability or the extent of colorectal hepatic metastasis (CHM), down-staged by chemotherapy.


METHODS
A retrospective lesion-by-lesion analysis was performed for seven consecutive patients, who had received rescue hepatectomy for initially unresectable CHM, in order to evaluate the correlation between results of imaging modalities and the corresponding pathology.


RESULTS
The sensitivity and positive predictive value of the conventional modalities (CT and MRI) were 92% and 42%, respectively, while the sensitivity, specificity, positive predictive value and negative predictive value of FDG-PET were 58%, 100%, 100% and 75% respectively. The sensitivity of FDG-PET was 100% in evaluating the viability of tumors >2 cm, however, this fell to 17% in tumors <2 cm.


CONCLUSIONS
FDG-PET is effective in assessing the viability of tumors >2 cm, but not those <2 cm, in patients with CHM down-staged by chemotherapy.
Takahashi
Shinichiro
S
Department of Hepato-biliary Pancreatic Surgery, National Cancer Center Hospital East, Chiba, Japan. shtakaha@east.ncc.go.jp
Kuroki
Yoshihumi
Y
Nasu
Katsuhiro
K
Nawano
Shigeru
S
Konishi
Masaru
M
Nakagohri
Toshio
T
Gotohda
Naoto
N
Saito
Norio
N
Kinoshita
Taira
T
D000328:Adult; D000368:Aged; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D003131:Combined Modality Therapy; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18